Vaginal Antifungals Market

Vaginal Antifungals Market Snapshot

The global vaginal antifungals market enjoys a valuation of USD 1.09 Billion in 2022, and it is further projected to expand at a CAGR of 4.5% over the forecasted years. According to a recent study by Future Market Insights, Polygenes are leading the market with a share of about 49.0% in the year 2022, within the global market.

Market Outlook

Data Points	Market Insights
Market Value 2022	USD 1.09 Billion
Market Value 2033	USD 1.76 Billion
CAGR 2023 to 2033	4.5%
Market Share of Top 5 Countries	61.7%
Key Market Players	Pfizer Inc., Bausch Health Companies Inc., ANI Pharmaceuticals, Inc., Hikma Pharmaceuticals Plc, Lupin Limited, Mycovia Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Unique Pharmaceuticals, PEPTONIC Medical AB, Aurobindo Pharma Limited, Dr. Reddy's Laboratories, SCYNEXIS Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A.Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc.

The signs of vaginal fungi infections include bloating near the vagina, burning when urinating, whitish-grey and clumpy vaginal discharge, and many others. Another name for vaginal yeast infection is candidiasis. Bacteria and a small number of yeast cells make up a healthy vagina, but when the ratio of bacteria to yeast changes, the yeast cells have the potential to multiply, which can further cause extreme itching, swelling, and irritation.

Antifungal medications prevent fungal infections from occurring by limiting the growth of fungus microorganisms on the host cell. As a result, the market is being favourably impacted by the availability of a variety of antifungal medications for the treatment of fungal infections as well as availability of over-the-counter medications.

Sales Analysis of Vaginal Antifungals Market from 2018 to 2022 Vs Market Outlook for 2023 to 2033.

The global sales of the market are anticipated to rise at a CAGR of 4.5% between 2023 and 2033, owing to the rising prevalence of vaginal infectious disease.

The global vaginal antifungals market holds around 7.4% share of the overall global antifungals drug market with a value of around USD 14.74 Billion, in 2022.

Vulvovaginal candidiasis (VVC), which mainly affects immunocompetent childbearing age women, frequently affects the lower female genital tract. Candida albicans is the pathogenic yeast that is most commonly linked to this fungus infection, excluding other non-albicans species.

Significant number of women, according to various scientists, have candida in their vaginas without exhibiting any signs. If the vaginal environment changes to favour Candida development, an infection may result. Hormones, medications, and immune system changes can all trigger infection. Additionally, among women of reproductive age, infectious organisms most frequently cause vulvovaginitis, or inflammation of the vulva and vagina. Candida vulvovaginitis is the root cause of around one-third of these instances.

The VVC emergence can be influenced by a variety of lifestyle factors. Although some studies suggest that excessive use of antibiotics and uncontrolled diabetes in women results in the vaginal fungal infections. Thus, the rising prevalence of diabetic patients in women is propelling the market.

Although, the market is being constrained by the reality that despite how many topical have been developed by the manufacturers, they are ineffective because they do not penetrate the skin well enough. However, the creation of novel products to enhance delivery, absorption, retention, and bioabsorbility in vulvovaginal tissue provides a significant market opportunity for manufacturers and drug developers.

Owing to the above-mentioned factors, the global market is expected to grow at a prominent pace, and reach a valuation of around USD 1.76 Billion during the year 2033.

What are the Key Opportunities for the Manufacturers Operating in the Global Market?

The market is anticipated to expand due to a rise in the vulvovaginal candidiasis in pregnant women and risk of fungal infection in diabetic patients.

Worldwide, pregnant women are affected by vulvovaginal candidiasis (VVC), a yeast infection of the vulva brought on by species of Candida. Due to a rise in the level of estrogen, which makes it easier for yeast to colonise the vagina pregnant women are more susceptible to developing VVC.

• According to the study titled "The incidence of VVC among pregnant women in the H.o. municipality, Ghana: the identification of species and antifungal resistance of Candida specimens," published in BMC Pregnancy Childbirth 2020, the prevalence of VVC was 30.7% among the participants in this investigation. Participants in the third trimester of pregnancy accounted for 57.4% of the VVC incidence. 81.5% of the 54 VVC-verified subjects had symptomatic VVC, while 18.5% had colonised VVC. These increased infection rates are due to higher oestrogen levels in the vagina of pregnant women. As a result of the rising frequency of VVC in pregnant women, there is a significant increase in antifungal demand.

Similarly, antifungals are in high demand due to an increase in the danger of fungal infections in diabetic patients. Diabetes Mellitus has been linked to a number of health problems in women, including yeast infection. Diabetes, or unregulated blood glucose levels, can cause yeast overgrowth in warm and moist regions of the body, especially the vagina.

• For example, as per an article titled "Risk of various infections in diabetes patients compared with the general population," which is submitted in Diabetic Care 2018, diabetes patients, whether they have type 1 or type 2, are more susceptible to infections, including yeast infections. Excess sugar in the blood ultimately leads to excess sugar in the urine, which leads to yeast overgrowth. Further, diabetes is projected to affect up to 642 million people worldwide, rising to 10.4% of the population by 2040.

As a result, the increased risk of fungal infection in diabetes patients, as well as the desire for curative medication, are driving market expansion.

What are the Factors Restraining Demand within the Global Market?

Due to medication side effects and a reduced detection rate as a result of asymptomatic fungal infections, the market is anticipated to slow down.

There is a need for the vaginal infections to be treated because the prevalence of fungi-related diseases is increasing globally. The absence of infection detection, however, is the main hindrance to market expansion. For instance, according to the Centers for Disease Control and Prevention, many fungi illnesses go undetected because of their vague symptoms. In addition, according to the article "Patient education: Bacterial vaginosis (Beyond the Basics)" in UpToDate 2023, around 50 to 75 percent of persons with BV have no symptoms. Hence, the lower detection rate is leading to a limited treatment rate for fungal infections, which is hampering the market.

Similar to this, the market is being gradually restrained by the negative effects of the medication used to treat vaginal fungal infections. For instance, vulvovaginal candidiasis is more common in pregnant women, making them essential for the treatment. Contrarily, animal studies by SCYNEXIS, Inc. suggest that administering the antifungal medication BREXAFEMME to pregnant women could damage the foetus. These serious drug side effects are preventing the industry from expanding. Additionally, diarrhoea, nausea, abdominal pain, and vomiting were the most frequent adverse reactions seen in clinical studies (incidence 2%). As a consequence, the market's development is constrained by the potent side effects of the drugs used to treat a fungus infection.

Country-wise Insights

What Makes the USA a Large Market for Vaginal Antifungals?

The USA dominates the global market with a total market share of around 27.0% in 2022, and the same rate of growth is anticipated to continue throughout the forecast period.

Rising prevalence of trichomoniasis in the country is supporting to the market growth for the vaginal antifungals.

Trichomoniasis can make it more probable for people to contract or spread HIV, and it increases the likelihood that women infected with the condition will deliver their babies prematurely and with low birth weights.

• According to the Centre for Disease Control and Prevention (CDC) for 2021, 2.1% of females in theUSA population have T. vaginalis (Trichomoniasis). As a result, the expenditures for fungal illnesses are increasing in the nation. For instance, as per the "Economic Burden of Fungal Diseases in the United States" study published in Open Forum Infectious Diseases 2022, the estimated 2019 economic impact of fungal infections was $11.5 billion.

Therefore, with the increasing burden of fungal infection diseases, the demand for cure treatments is increasing, which is raising the market.

What is the Outlook of China in the Vaginal Antifungals Market?

China has a market share of 12.8% in the global vaginal antifungals market in 2022 due to the upsurge in the high quality health care service in by the government.

As the cornerstone of integrated care, the Chinese government began to investigate the hierarchical diagnostic and treatment system. An institutional innovation in health care reform is the development of medical alliances, which enables hospitals and primary health care (PHC) facilities to collaborate closely to offer disease prevention, treatment, and rehabilitation services across the life course. By the end of 2019, China have created 12,000 medical alliances in order to mobilise high-quality healthcare services from public hospitals to PHC facilities.

• Similar to this, the total number of PHC facilities in 2021 has risen by 7.1% compared to 2012, reaching 978,000 according to the study "Primary health care in China: A decade of development after the 2009 health care reform" in Wiley Online Library 2022.

What is the Scenario of Germany within the Vaginal Antifungals Market Space?

Germany holds a market share of 7.6% in 2022 in the global vaginal antifungals market, owing to the government flutter to combat the infectious diseases.

Since 2016, Germany has been a steadfast supporter of Global Antibiotic Research and Development Partnership (GARDP) and has taken the lead in initiatives to combat antibiotic resistance. German government continues to be the largest contributor to GARDP with the new financing, increasing the entirety of its expenditures to EUR 116 million. Over the following five years (2023-2027), the German Federal Ministry of Education and Research pledged a further EUR 50 million in funds for the GARDP. The German financing will enable GARDP to develop novel antibiotic-resistant sickness therapies and ensure that everyone who requires them has access to them.

As a result, increased government funding for antibiotic resistance drugs is propelling the country's vaginal antifungals market.

Will The India Be a Lucrative Market for Vaginal Antifungals?

India has a market share of 8.6% in the global vaginal antifungals market in 2022 due to the rising prevalence of vulvovaginal candidiasis.

Vulvovaginal candidiasis (VVC) is a clinical disease that is frequently seen in India. At least one episode of VVC occurs in at least three-fourths of all women's lifetimes. According to a study published in the Indian Journal of Obstetrics and Gynaecology Research, titled Vulvovaginal Candidiasis: Epidemiology, Treatment, and Prevention Strategies, the prevalence of VVC in India ranges from 10 to 35%.

So, topical treatments for short courses are useful in treating straightforward VVC. In 80%–90% of patients who complete therapy, azole treatment relieves symptoms and produces negative cultures according to CDC 2021. The success of oral and topical therapies for the VVC has led to an increase in the demand for antifungals.

Category-wise Insights

Which Vaginal Antifungals Product is Driving the Market Growth?

Polygenes are expected to give high growth to the market and holding around 49.0% market share in 2022.

All common fungi that cause systemic infection, including species of Candida, Aspergillus, Mucor, and Cryptococcus, are responsive to amphotericin (belongs to the polyene class of antifungals). For infections caused by the aforementioned species, polyenes are very effective, which is leading to their high adoption. These medications are thought to be the most affordable, secure, and low-toxic antifungal agents available. Therefore, the demand is increasing because polyenes have fewer negative effects.

Which Route of Administration is Largely of Adopted within the Global Market?

Topical administration is mostly preferred by the healthcare professional for the treatment purpose. It has a market share of 73.1% in the global market in 2022.

Due to their tailored therapy and limited adverse effects, topical fungal therapies are typically favoured. Due to their unique functional and structural characteristics, advanced topical transporters get beyond biopharmaceutical issues with traditional drug delivery systems, such as poor retention and low bioavailability. Additionally, continuous usage of antifungal medications has the potential to have negative side effects. In order to address this problem, patient cooperation is directed towards topical infection treatment. As a result, the market leader is the topical treatment category.

Which Indication is Dominating Vaginal Antifungals?

Bacterial vaginosis holds the market share of 44.9% during the year 2022.

A bacterial imbalance results in overgrowth of bacteria, which leads to bacterial vaginosis (BV), a common vaginal infection. The risk of bacterial vaginosis in pregnant women is increasing, which is also driving market expansion. Preterm birth, early miscarriage, postpartum endometritis, low birth weight, has been observed in women with bacterial vaginosis during pregnancy.

Which Distribution Channel Benefits the Most from the Sales within the Market?

Gynaecology Clinics hold a market share of 41.4% during the year 2022. It is due to the high priority for the gynaecology clinics by the patients. The availability of specialised clinicians and high-tech treatment equipment attracts people to gynaecology clinics. Furthermore, the rising prevalence of vaginal infectious illnesses, combined with increased investment in infrastructure development, is increasing the usage of gynaecology clinics.

Competitive Landscape

Leading companies in the global vaginal antifungals market are seeking for possibilities such as regional expansion to improve their market share. Furthermore, in order to boost their market presence, local rising companies are employing different methods such as mergers, cooperation, acquisition, agreement, and product launches and development in the vaginal antifungals market.

• Scynexis announced in June 2021 that Brexafemme had been approved by the US Food and Drug Administration for the management of vaginal yeast infections.
• On April 28, 2022 - VIVJOA (oteseconazole pills) from Mycovia Pharmaceuticals has been approved by the US Food and Drug Administration (FDA). The FDA's first and only drug for treating recurrent vulvovaginal candidiasis (chronic yeast infection)

Similarly, recent developments related to companies manufacturing vaginal antifungals products have been tracked by the team at Future Market Insights. These are available in the full report.

Report Scope as per Vaginal Antifungals Industry Analysis

Attribute	Details
Forecast Period	2018 to 2022
Historical Data Available for	2023 to 2033
Market Analysis	USD Million for Value
Key Regions Covered	North America; Latin America; Europe; South Asia; East Asia; Oceania; and the Middle East & Africa
Key Countries Covered	The USA, Canada, Brazil, Mexico, Argentina, The United kingdom, Germany, Italy, Russia, Spain, France, Benelux, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Türkiye, GCC Countries and South Africa
Key Market Segments Covered	Product, Route of Administration, Indication, Distribution Channel, and Region
Key Companies Profiled	Pfizer Inc.; Bausch Health Companies Inc; ANI Pharmaceuticals, Inc.; Hikma Pharmaceuticals Plc; Lupin Limited; Mycovia Pharmaceuticals, Inc.; Glenmark Pharmaceuticals Limited; GSK plc.; Aurobindo Pharma Limited; Dr. Reddy's Laboratories; SCYNEXIS, Inc.; Basilea Pharmaceutica Ltd.; Astellas Pharma Inc.; Grupo Ferrer Internacional, S.A.; Pacgen Life Science Corporation; NovaDigm Therapeutics, Inc.; Cidara Therapeutics, Inc.; Amplyx Pharmaceuticals Inc.
Report Coverage	Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Pricing	Available upon Request

Key Market Segments Covered in the Vaginal Antifungals Industry Research

By Product:

• Polyenes
• Azoles
• Allylamines
• Echinocandins
• Others

By Route of Administration:

• Oral
• Topical

By Indication:

• Bacterial Vaginosis
• Candidiasis
• Trichomoniasis
• Others

Distribution Channel:

• Hospital Pharmacies
• Supermarkets/hypermarkets
• Online Pharmacies
• Gynaecology Clinics
• Others

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• The Middle East and Africa (MEA)

Frequently Asked Questions

What is the Vaginal Antifungals Market’s Growth Potential?

The CAGR of the market is 4.5% through 2033.

What is the Projected Size of The Market by 2033?

The global market size to reach USD 1.76 Billion by 2033.

What is the Market Share of the United States?

With a market share of 27.0%, the United States governs the global market.

What is the Market Share of China?

China possesses a 12.8% market share in the market.

Which Factor is the Main Market Restraint?

The market has slowed notably owing to side effects from drugs and a lower identification rate as a consequence of asymptomatic fungal infections.

What are the Core Opportunities for The Manufacturers?

Due to a spike in vulvovaginal candidiasis in pregnant ladies and the potential of fungal infection in diabetics, the market is set to expand.